VIR-5500 ASCO GU update, VIR-5818 H2’26, ECLIPSE 1 Q4’26 + more hepatitis delta readouts. See more details here.

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

Join 19 News for extensive coverage of the 2024 Total Solar Eclipse starting on Monday, April 8, with 19 News at Noon. 19 News will be live with LIGHTS OUT IN THE LAND coverage from locations all over ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...

ECLIPSE ABOUT WHAT SCIENTISTS ARE LOOKING FORWARD TO. WE ARE JUST DAYS AWAY FROM A RARE CELESTIAL EVENT A TOTAL ECLIPSE OF THE SUN ON APRIL 8TH. MORE THAN 31 MILLION PEOPLE WILL BE IN THE PATH OF ...